IngentaConnect Search Results

NSAID-Associated Adverse Effects and Acid Control Aids to Prevent Them: A Review of Current Treatment Options

Authors: Næsdal, Jørgen; Brown, Kurt

Source: Drug Safety, Volume 29, Number 2, 2006 , pp. 119-132(14)

Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors

Authors: Gambero, Alessandra; Becker, Tagliane Liza; Zago, Andréa Silva; de Oliveira, Andréa Fermino; Pedrazzoli, José

Source: Inflammopharmacology, Volume 13, Numbers 5-6, 2005 , pp. 441-454(14)

Publisher: VSP, an imprint of Brill

Importance of the pineal gland, endogenous prostaglandins and sensory nerves in the gastroprotective actions of central and peripheral melatonin against stress-induced damage

Authors: Brzozowski, Tomasz; Konturek, Peter C.; Zwirska-Korczala, Krystyna; Konturek, Stanislaw J.; Brzozowska, Iwona; Drozdowicz, Danuta; Sliwowski, Zbigniew; Pawlik, Michal; Pawlik, Wieslaw W.; Hahn, Eckhart G.

Source: Journal of Pineal Research, Volume 39, Number 4, November 2005 , pp. 375-385(11)

Publisher: Blackwell Publishing

Development of intestinal, but not gastric damage caused by a low dose of indomethacin in the presence of rofecoxib

Authors: Yokota, Aya; Taniguchi, Masaki; Tanaka, Akiko; Takeuchi, Koji

Source: Inflammopharmacology, Volume 13, Numbers 1-3, 2005 , pp. 209-216(8)

Publisher: VSP, an imprint of Brill

Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologist's Perspective

Authors: Lehmann, F. S.; Beglinger, C.

Source: Current Topics in Medicinal Chemistry, Volume 5, Number 5, June 2005 , pp. 449-464(16)

Publisher: Bentham Science Publishers

COX Inhibition and NSAID-Induced Gastric Damage - Roles in Various Pathogenic Events

Authors: Takeuchi, K.; Tanaka, A.; Hayashi, Y.; Yokota, A.

Source: Current Topics in Medicinal Chemistry, Volume 5, Number 5, June 2005 , pp. 475-486(12)

Publisher: Bentham Science Publishers

Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs

Authors: M. MOREAU; S. DAMINET; J. MARTEL-PELLETIER; J. FERNANDES; J.-P. PELLETIER

Source: Journal of Veterinary Pharmacology & Therapeutics, Volume 28, Number 1, February 2005 , pp. 81-86(6)

Publisher: Blackwell Publishing

Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations

Authors: Lazzaroni, M.; Bianchi Porro, G.

Source: Alimentary Pharmacology & Therapeutics, Volume 20, Supplement 2, July 2004 , pp. 48-58(11)

Publisher: Blackwell Publishing

Functional Mechanism Underlying COX-2 Expression Following Administration of Indomethacin in Rat Stomachs: Importance of Gastric Hypermotility

Authors: Takeuchi K.; Tanaka A.; Hayashi Y.; Kubo Y.

Source: Digestive Diseases and Sciences, Volume 49, Number 2, February 2004 , pp. 180-187(8)

Publisher: Springer

Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat

Authors: Abdel-Salam O.M.E.; Baiuomy A.R.; El-batran S.; Arbid M.S.

Source: Pharmacological Research, Volume 49, Number 2, February 2004 , pp. 133-142(10)

Publisher: Elsevier

COX-2 Inhibition, H. pylori Infection and the Risk of Gastrointestinal Complications

Author: Chan, Francis K.L.

Source: Current Pharmaceutical Design, Volume 9, Number 27, October 2003 , pp. 2213-2219(7)

Publisher: Bentham Science Publishers

Valdecoxib: A review

Authors: Chavez M.L.; DeKorte C.J.

Source: Clinical Therapeutics, Volume 25, Number 3, March 2003 , pp. 817-851(35)

Publisher: Elsevier

Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury

Authors: Tanaka, A.; Araki, H.; Hase, S.; Komoike, Y.; Takeuchi, K.

Source: Alimentary Pharmacology & Therapeutics, Volume 16, Supplement 2, April 2002 , pp. 90-101(12)

Publisher: Blackwell Publishing

Valdecoxib

Authors: Ormrod D.; Wellington K.; Wagstaff A.J.

Source: Drugs, Volume 62, Number 14, 2002 , pp. 2059-2071(13)

Publisher: Adis International

Gastrointestinal Damage Induced by Celecoxib and Rofecoxib in Rats

Authors: Laudanno O.M.; Cesolari J.A.; Esnarriaga J.; Rista L.; Piombo G.; Maglione C.; Aramberry L.; Sambrano J.; Godoy A.; Rocaspana A.

Source: Digestive Diseases and Sciences, Volume 46, Number 4, April 2001 , pp. 779-784(6)

Publisher: Springer

Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs

Authors: Tanaka A.; Araki H.; Komoike Y.; Hase S.; Takeuchi K.

Source: Journal of Physiology-Paris, Volume 95, Number 1, January 2001 , pp. 21-27(7)

Publisher: Elsevier

COX-2 Selective Nonsteroidal Anti-Inflammatory Drugs: Do They Really Offer Any Advantages?

Authors: Jackson L.M.; Hawkey C.J.

Source: Drugs, Volume 59, Number 6, June 2000 , pp. 1207-1216(10)

Publisher: Adis International

Good postmarketing surveillance of the new cyclo-oxygenase (COX)-2 inhibitor rofecoxib [`Vioxx'] is `vital'

Source: Reactions, Volume 1, Number 758, 1999 , pp. 3-3(1)

Publisher: Adis International

Rofecoxib studies indicate no GI damage

Source: Reactions, Volume 1, Number 724, 1998 , pp. 2-2(1)

Publisher: Adis International